Share this:
November 2019
Volume 1 about us for patients for doctors resources events news

Dear Friends,

We’re excited to share with you a new study for patients with neuroendocrine tumors (NETs)
who have switched from monthly Sandostatin LAR® (octreotide) to Somatuline® Depot (lanreotide) injections within the past 12 months. If you are 21 years or older and live in the United States, we invite you to see if you are eligible to participate. Please check this out today because there are a limited number of individuals who can participate in the study.

The goals of the study are to explore the differences between the 2 somatostatin analog (SSA) injections, to understand preferences for SSA treatment among NET patients, and to describe the reasons for the change from Sandostatin LAR® (octreotide) to Somatuline® Depot (lanreotide). By participating in the study you can help raise awareness about treatment options for NET patients and their experience with SSA treatment.

If you are interested in participating, please follow the link below to take a brief (5-10 minute) screening survey to determine if you are eligible for the study. If you qualify based on the screening survey, you will be scheduled for a telephone interview with our research partner so we  can learn more about your experiences with NETs and their treatment.  The interview will be scheduled for a time that is convenient for you, and should take about one hour.

Immediately upon completion of the interview, in appreciation for your time, a Visa gift card in the amount of $100 will be mailed to you. 
Please click here to see if you qualify for the study:
Your decision to take part in this study is completely voluntary and your responses will be kept confidential. 

This research study is being conducted by Pharmerit International on behalf of a pharmaceutical company to gain a better understanding of patients’ experiences with monthly long-acting SSA injections to treat NETs. Pharmerit is a research organization that conducts studies to provide information on how patients experience health conditions and their treatments, and is partnering with the Carcinoid Cancer Foundation to recruit participants for the study.

If you have any questions about the study, you can contact the Pharmerit research team by phone at 240-863-0014 or by email at

Your voice makes a difference for NET patients. Thank you in advance for your interest in this study!

With appreciation,

The Carcinoid Cancer Foundation Team
The Carcinoid Cancer Foundation's educational, awareness and advocacy activities are made possible by your contributions.  These crucial activities lead toward early detection, improving the quality of life for cancer survivors, and ultimately to a cure. The Carcinoid Cancer Foundation is a 501(c)(3) nonprofit organization.  All contributions to the Carcinoid Cancer Foundation are tax-deductible to the extent allowed by law. Thank you for your support. 
Carcinoid Cancer Foundation
118 North Bedford Road, Suite 100
Mt. Kisco, NY 10549
Phone: 888.722.3132
facebook twitter You tube Blog
118 N. Bedford Road Suite 100 | Mt. Kisco, NY 10549-2555 US
powered by emma
Subscribe to our email list.